135 related articles for article (PubMed ID: 18946065)
1. Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Jackevicius CA; Tu JV; Demers V; Melo M; Cox J; Rinfret S; Kalavrouziotis D; Johansen H; Behlouli H; Newman A; Pilote L
N Engl J Med; 2008 Oct; 359(17):1802-10. PubMed ID: 18946065
[TBL] [Abstract][Full Text] [Related]
2. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
[TBL] [Abstract][Full Text] [Related]
3. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Lewis BS; Mehta SR; Fox KA; Halon DA; Zhao F; Peters RJ; Keltai M; Budaj A; Yusuf S;
Am Heart J; 2005 Dec; 150(6):1177-84. PubMed ID: 16338255
[TBL] [Abstract][Full Text] [Related]
4. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy.
Pride YB; Wiviott SD; Buros JL; Zorkun C; Tariq MU; Antman EM; Braunwald E; Gibson CM;
Am Heart J; 2009 Sep; 158(3):e21-6. PubMed ID: 19699846
[TBL] [Abstract][Full Text] [Related]
5. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
L'Allier PL; Aronow HD; Cura FA; Bhatt DL; Albirini A; Schneider JP; Topol EJ; Ellis SG
Can J Cardiol; 2003 Aug; 19(9):1041-6. PubMed ID: 12915931
[TBL] [Abstract][Full Text] [Related]
7. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial.
Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Mark B; Zahn R; Senges J; Gottwik M
Thromb Haemost; 2008 Jan; 99(1):155-60. PubMed ID: 18217148
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge.
Tricoci P; Roe MT; Mulgund J; Newby LK; Smith SC; Pollack CV; Fintel DJ; Cannon CP; Bhatt DL; Gibler WB; Ohman EM; Peterson ED; Harrington RA
Arch Intern Med; 2006 Apr; 166(7):806-11. PubMed ID: 16606819
[TBL] [Abstract][Full Text] [Related]
11. Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation.
Wolak A; Amit G; Cafri C; Gilutz H; Ilia R; Zahger D
Int J Cardiol; 2005 Sep; 103(3):293-7. PubMed ID: 16098392
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
Baber U; Akhter M; Kothari S; Sharma SK; Kini A
J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
[TBL] [Abstract][Full Text] [Related]
13. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome.
Lemesle G; Delhaye C; Sudre A; Broucqsault D; Rosey G; Bauters C; Lablanche JM
Am Heart J; 2009 Feb; 157(2):375-82. PubMed ID: 19185648
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
18. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care.
Ho PM; Tsai TT; Maddox TM; Powers JD; Carroll NM; Jackevicius C; Go AS; Margolis KL; DeFor TA; Rumsfeld JS; Magid DJ
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):261-6. PubMed ID: 20407117
[TBL] [Abstract][Full Text] [Related]
19. [Optimal platelet inhibition after coronary stent implantation. Current status].
Silber S; Hoffmeister HM; Bode C
Herz; 2008 Jun; 33(4):244-53. PubMed ID: 18581073
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
